Catalyst Wire Dossier Catalyst Wire Dossier

HRS9531

· Fujian Shengdi Pharmaceutical Co., Ltd.
Drug timelines are a Plus or Pro feature.

22 regulatory and trial events tracked for HRS9531, covering 2023-09-26 to 2026-07-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes [Phase 3]

See pricing